2022-501089-22-00RecruitingPhase 1
Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-protein 4 agent associated with cytotoxic T lymphocytes in patients with advanced solid tumors.
Italfarmaco S.p.A.7 sites in 2 countries60 target enrollmentStarted: November 9, 2022Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 60
- Locations
- 7
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Maurizio Caserini
Scientific
Italfarmaco S.p.A.
Study Sites (7)
Loading locations...
Similar Trials
Recruiting
Phase 2
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).2022-501250-12-01Sparingvision17
Recruiting
Phase 1
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.2023-507059-32-00VarmX B.V., VarmX B.V.48
Completed
Phase 1
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of healthy Japanese participants2023-503891-26-00Novo Nordisk A/S170
Recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants2024-512939-67-00Mindstate Design Labs Inc.68
Completed
Phase 1
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia2023-508819-23-00Hutchmed Ltd.22